Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Managing oligoprogressive kidney cancer with radiation therapy

Chad Tang • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer

Chad Tang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, examines the challenge presented by oligoprogressive kidney cancer – where certain lesions grow despite effective systemic therapy. Dr Tang describes a randomized study investigating whether targeted radiation therapy can control these progressing sites while allowing patients to remain on their current treatment. This approach aims to extend the effectiveness of systemic therapy and delay the need for a new line treatment. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Chad Tang

KIM-1 and ctDNA as prognostic markers in oligometastatic ccRCC
0:48
KIM-1 and ctDNA as prognostic markers in oligometastatic ccRCC
Chad Tang • 28 Feb 2026
The role of PSMA PET in metastatic prostate cancer staging
0:37
The role of PSMA PET in metastatic prostate cancer staging
Chad Tang • 14 Feb 2025
Evaluating metastasis-directed therapy in oligometastatic prostate cancer
0:47
Evaluating metastasis-directed therapy in oligometastatic prostate cancer
Chad Tang • 14 Feb 2025
Potential of de-escalating systemic cancer therapies in GU cancers
0:37
Potential of de-escalating systemic cancer therapies in GU cancers
Chad Tang • 27 Oct 2022

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals